Patents by Inventor Jaeil SHIN

Jaeil SHIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RECOMBINANT VACCINIA VIRUS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
    Publication number: 20220347244
    Abstract: A recombinant vaccinia virus containing a gene encoding sPD-1 or hyaluronidase and a pharmaceutical composition including the same are disclosed. The recombinant vaccinia virus containing a cancer therapy gene and having suppressed expression of K3L, TK, or VGF gene of the vaccinia virus has an excellent anti-tumor effect. Therefore, the recombinant vaccinia virus of the present invention can be advantageously used in cancer treatment.
    Type: Application
    Filed: January 18, 2019
    Publication date: November 3, 2022
    Applicant: KOLON LIFE SCIENCE, INC.
    Inventors: Sujeong KIM, Heonsik CHOI, Minjung KIM, Jaeil SHIN, Soonoh HONG, Hyesun LEE, Soondong LEE, Hwanjun CHOI, Joonsung KIM, Jieun HONG, Eunjin LEE, Haesu KANG
  • Recombinant vaccinia virus and use thereof
    Patent number: 11452770
    Abstract: The present invention relates to a recombinant vaccinia virus in which the expression of some genes is inhibited, and a use thereof. The recombinant vaccinia virus of the present invention selectively kills cancer cells, and has an excellent reproducibility in cancer cells. Also, the virus has a lower toxicity to normal cells, and thus has an advantage of being safe for a human body. Therefore, the recombinant vaccinia virus of the present invention can be effectively used as a composition for treating cancer.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 27, 2022
    Assignee: KOLON LIFE SCIENCE, INC.
    Inventors: Sujeong Kim, Minjung Kim, Heonsik Choi, Jaeil Shin, Minju Kim, Hyesun Lee, Soondong Lee, Hwanjun Choi, Joonsung Kim, Jieun Hong, Eunjin Lee
  • RECOMBINANT VACCINIA VIRUS AND USE THEREOF
    Publication number: 20190247487
    Abstract: The present invention relates to a recombinant vaccinia virus in which the expression of some genes is inhibited, and a use thereof. The recombinant vaccinia virus of the present invention selectively kills cancer cells, and has an excellent reproducibility in cancer cells. Also, the virus has a lower toxicity to normal cells, and thus has an advantage of being safe for a human body. Therefore, the recombinant vaccinia virus of the present invention can be effectively used as a composition for treating cancer.
    Type: Application
    Filed: July 21, 2017
    Publication date: August 15, 2019
    Applicant: KOLON LIFE SCIENCE, INC.
    Inventors: Sujeong KIM, Minjung KIM, Heonsik CHOI, Jaeil SHIN, Minju KIM, Hyesun LEE, Soondong LEE, Hwanjun CHOI, Joonsung KIM, Jieun HONG, Eunjin LEE